Peroxisome proliferator-activated receptor α (PPARα) plays important roles in lipid metabolism. A recently discovered L162V polymorphism of the PPARα gene is associated with enhanced transcriptional activity. In this study, the frequency of L162V was investigated in nonalcoholic steatohepatitis (NASH) and genotype 1 hepatitis C virus (HCV)-related liver steatosis.
Methods
Seventy-two NASH and 141 HCV-infected patients (54 with steatosis, 87 without steatosis) and 119 healthy controls were included. L162V polymorphism of the PPARα gene was analyzed by polymerase chain reaction (PCR) and restriction fragment length polymorphism (RFLP).
Results
PCR and RFLP analysis of the related gene segment was successful in 93%, 96%, and 100% of NASH and HCV-infected patients and controls, respectively. The frequency of the L162V polymorphism was similar in the NASH and HCV-infected patients and controls (5.9%, 3.6%, and 2.5%, respectively). No difference in the frequency of this polymorphism was observed in HCV-infected patients with or without significant liver steatosis. L162V was not associated with obesity, type 2 diabetes mellitus, hypercholesterolemia, or hypertriglyceridemia.
Conclusions
Neither NASH nor genotype 1 HCV-related liver steatosis seems to be associated with the PPARα L162V polymorphism. This polymorphism may have no association with the presence of type 2 diabetes mellitus, obesity, or various blood lipid alterations in NASH and HCV-infected patients.
BruntEM.Nonalcoholic steatohepatitis. definition and pathology. Semin Liver Dis2001;21:3–6.
2.
CaldwellSH, OelsnerDH, IezzoniJC. Cryptogenic cirrhosis. clinical characterization and risk factors for underlying disease. Hepatology1999;29:664–9.
3.
LudwigJ, ViggianoTR, McGillDB, OhBJ.Non-alcoholic steatohepatitis. Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc1980;55:434–8.
4.
Falck-YtterY, YounossiZM, MarchesiniG, McCulloughAJ.Clinical features and natural history of nonalcoholic steatosis syndromes. Semin Liver Dis2001;21:17–26.
MarchesiniG, BugianesiE, ForlaniG. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology2003;37:917–23.
7.
ChitturiS, AbeygunasekeraS, FarrellGC. NASH and insulin resistance. insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology2002;35:373–9.
8.
Neuschwander-TerriBA, CaldwellS.Nonalcoholic steatohepatitis. summary of an AASLD Single Topic Conference. Hepatology2003;37:1202–19.
9.
SanyalAJ, Campbell-SargentC, MirshahiF. Nonalcoholic steatohepatitis. association of insulin resistance and mitochondrial abnormalities. Gastroenterology2001;120:1183–92.
10.
AnguloP, LindorKD.Insulin resistance and mitochondrial abnormalities in NASH. a cool look into a burning issue. Gastroenterology2001;120:1281–4.
11.
GreenRM.NASH. hepatic metabolism and not simply the metabolic syndrome. Hepatology2003;38:14–7.
12.
ChitturiS, FarrellGC.Etiopathogenesis of nonalcoholic steatohepatitis. Semin Liver Dis2001;21:27–41.
13.
RaoMS, ReddyJK.Peroxisomal b-oxidation and steatohepatitis. Semin Liver Dis2001;21:43–55.
14.
YounossiZM, DiehlAM, OngIP.Nonalcoholic fatty liver disease. an agenda for clinical research. Hepatology2002;35:746–52.
15.
IssemannI, GreenS.Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature1990;347:645–50.
16.
DesvergneB, WahliBW.Peroxisome proliferator-activated receptors. nuclear control of metabolism. Endocr Rev1999;20:649–88.
17.
AkbiyikF, RayDM, BozkayaH, DemirpenceE.Ligand and species dependent activation of PPARα. Cell Physiol Biochem2004;14:269–76.
18.
HashimotoT, CookWS, QiC. Defect in peroxisome proliferator-activated receptor alpha-inducible fatty acid oxidation determines the severity of hepatic steatosis in response to fasting. J Biol Chem2000;275:28918–28.
19.
JohnsonEF, PalmerCN, GriffinKJ, HsuMH.Role of the peroxisome proliferator-activated receptor in cytochrome P450 4A gene regulation. FASEB J1996;10:1241–8.
20.
LeeSS, PineauT, DragoJ. Targeted disruption of the alpha isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators. Mol Cell Biol1995;15:3012–22.
21.
ReddyJK.Nonalcoholic steatosis and steatohepatitis III. Peroxisomal b-oxidation, PPAR alpha, and steatohepatitis. Am J Physiol Gastrointest Liver Physiol2001;281.G1333–9.
22.
FanCY, PanJ, UsudaN. Steatohepatitis, spontaneous peroxisome proliferation and liver tumors in mice lacking peroxisomal fatty acyl-CoA oxidase. J Biol Chem1998;273:15639–45.
23.
FanCY, PanJ, ChuR. Hepatocellular and hepatic peroxisomal alterations in mice with a disrupted peroxisomal fatty acyl-coenzyme A oxidase gene. J Biol Chem1996;271:24698–710.
24.
AkbiyikF, CinarK, DemirpenceE. Ligand induced expression of peroxisome proliferator-activated receptor alpha and activation of fatty acid oxidation enzymes in fatty liver. Eur J Clin Invest2004;34:429–35.
25.
HashimotoT, FujitaT, UsudaN. Peroxisomal and mitochondrial fatty acid b-oxidation in mice nullizygous for both peroxisome proliferator-activated receptor alpha and peroxisomal fatty acyl-CoA oxidase. Genotype correlation with fatty liver phenotype. J Biol Chem1999;274:19228–36.
26.
FlavellDM, PinedaTorra I, JamshidiY. Variation in the PPAR alpha gene is associated with altered function in vitro and plasma lipid concentrations in type II diabetic subjects. Diabetologia2000;43:673–80.
27.
VohlMC, LepageP, GaudetD. Molecular scanning of the human PPAR alpha gene. association of the L162V mutation with hyperapobetalipoproteinemia. J Lipid Res2000;41:945–52.
28.
TaiES, DemissieS, CupplesLA. Association between the PPAR alpha L162V polymorphism and plasma lipid levels. The Framingham offspring study. Arterioscler Thromb Vasc Biol2002;22:805–10.
29.
RobitailleJ, BrouilletteC, HoudeA. Association between PPAR alpha-L162V polymorphism and components of the metabolic syndrome. J Hum Genet2004;49:482–9.
30.
EvansD, AberleJ, WendtD. A polymorphism, L162V, in the PPAR alpha gene is associated with lower body mass index in patients with non-insulin-dependent diabetes mellitus. J Mol Med2001;79:198–204.
31.
RamalhoF.Hepatitis C viral infection and liver steatosis. Antiviral Res2003;60:125–7.
32.
HezodeC, Roudot-ThoravalF, ZafraniES. Different mechanisms of steatosis in hepatitis C virus genotypes 1 and 3 infections. Viral Hepat2004;11:455–8.
33.
BozdayiAM, AslanN, BozdayiG. Molecular epidemiology of hepatitis B, C and D viruses. Arch Virol2004;149:2115–29.
34.
KnodellRG, IshakKG, BlackWC. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology1981;1:431–5.
35.
BruntEM, JanneyCG, Di BisceglieAM. Nonalcoholic steatohepatitis. a proposal for grading and staging the histological lesions. Am J Gastroenterol1999;94:2467–74.
36.
Gouni-BertholdI, GiannakidouE, Muller-WielandD. Association between the PPAR alpha L162V polymorphism, plasma lipoprotein levels, and atherosclerotic disease in patients with diabetes mellitus type 2 and in non-diabetic controls. Am Heart J2004;147:1117–24.
37.
LonardoA, AdinolfiLE, LoriaP. Steatosis and hepatitis C virus. mechanisms and significance for hepatic and extrahepatic disease. Gastroenterology2004;126:586–97.
38.
RatziuV, TrabutJB, PoynardT. Fat, diabetes and liver injury in chronic hepatitis C. Curr Gastroenterol Rep2004;6:22–9.
